Philippine Health Research Registry
Display Options
Results List
Results 1 - 17 of 17 research(es) under Angeles University Foundation Medical Center

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Completed
Project Description:
Phase 3, multicenter, randomized, double-blind, placebocontrolled, parallel-group, outpatient study examining the effect of LY2127399 120 mg Q4W and 120 mg Q2W versus placebo in patients with active SLE who may be receiving concomitant SoC.
Project Status:
Completed
Project Description:
Study H9B-MC-BCDX (BCDX) is an open-label extension (OLE) study that assesses the longterm safety and efficacy of LY2127399 in patients with SLE who may be receiving concurrent standard of care (SoC) from 2 double-blind, Phase 3 Studies H9B-MC-BCDS (BCDS) and H9BMC- BCDT (BCDT).
Project Status:
Ongoing
Project Description:
The primary hypothesis is that additional LDL-C lowering with AMG 145 when used in addition to other treatment for dyslipidemia is well tolerated and decreases the aggregate risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, and coronary revascularization in subjects with clinically evident cardiovascu... [read more]
Project Status:
Ongoing
Project Description:
This is a global, multi-center, randomized, placebo-controlled study to evaluate adverse events of special interest in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) treated with belimumab plus standard therapy vs placebo plus standard therapy. Approximately 5,000 subjects will be randomized to 1 of 2 treatment groups:... [read more]
Project Status:
Completed
Project Description:
The combination of ETN 50 mg once weekly plus MTX ( other DMARDs) therapy with that of MTX ( other DMARDs) at Week 52 in subjects with moderately to severely active RA who have achieved LDA (DAS28-ESR<3.2) after 24 weeks of therapy with open-label ETN 50 mg once weekly plus MTX ( other DMARDs) in a treat to target paradigm.
Project Status:
Ongoing
Project Description:
This is a Phase IIb, multicenter, double-blind, placebocontrolled (DBPC) parallel-arm trial in which subjects are planned to be randomized in a ratio of 1:1:1 to receive placebo, or atacicept 75 mg or 150 mg, given as once weekly subcutaneous (SC) injections for 24 weeks. The trial is composed of a screening period, a DBPC treatment period, and a s... [read more]
Project Status:
Ongoing
Project Description:
This is a phase IIb, multi-center, LTE trial in which subjects will receive atacicept 75 or 150 mg, given as once weekly (QW) subcutaneous (SC) injections. Eligible subjects who complete the 24-week treatment period of EMR-700461-023 (ADDRESS II core trial, also referred to as the “core trial”) and enter this LTE trial will have treatment assig... [read more]
Project Status:
Terminated
Project Description:
Clinical Phase: IIIDuration of treatment: Each patient will be treated with either BI 695501 or US-sourced Humira® every 2 weeks. The trial will consist of a Screening period of up to a maximum of 46 days, a pre-randomization phase of up to 10 days, and a 48-week treatment period.Every effort should be made for all patients who complete the total ... [read more]
Project Status:
Ongoing
Project Description:
Phase IIIbStudy Duration: 24 monthsThis study is a randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe ... [read more]
Project Status:
Terminated
Project Description:
Study of safety of Foradil in patients with persistent asthma.
Project Status:
Terminated
Project Description:
This study is a Phase 3, double blind, placebo controlled, randomized, stratified, parallel group, multi-center clinical trial designed to compare the efficacy and safety of bococizumab 150 mg SC Q2wks to placebo for LDL-C lowering in subjects with primary hyperlipidemia or mixed dyslipidemia at high or very high risk for CV events. The study will ... [read more]
Project Status:
Ongoing
Project Description:
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalizat... [read more]
Project Status:
Ongoing
Project Description:
This is a phase 2, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of BIIB059 in subjects with systematic lupus erythematous and active skin manifestations and in subjects with active cutaneous lupus erythematous with or without systematic manifestations. This study will take place at approximately 95 centers i... [read more]
Project Status:
Pending
Project Description:
Study A391192 is a phase 3b/4 randomized double blind placebo controlled study of methotrexate (MTX) withdrawal in subjects with RA treated with tofacitinib 11mg MR formulation.   The study objective is to compare the efficacy of tofacitinib MR 11mg monotherapy to tofacitinib MR 11mg with continued MTX, as measured by the change in the Disease Act... [read more]
Project Status:
Ongoing
Project Description:
This is a Phase II, multicenter, international, randomized, double-blind, placebo-controlled (DBPC) parallel-arm trial, designed to determine the efficacy, dose response, and safety of M2951 in subjects with Systemic Lupus Erythematosus (SLE), and to consider a dose to take forward into Phase III development.Systemic lupus erythematosus (SLE), also... [read more]
Project Status:
Ongoing
Project Description:
A multicenter, randomized, double-blind, active-controlled, parallel-group phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following acute myocardial infarction
Project Status:
Ongoing
Project Description:
This is a Phase 3, multicenter, randomized, prospective, double-blind, parallel-group, placebo-controlled, 2-arm comparison study of Orelvo versus matching placebo. Subjects who have provided a signed and dated informed consent will be screened into the study up to 30 days before randomization. During the screening period, eligibility criteria will... [read more]